ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Olanzapine

Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.

Drug pageOlanzapine: every studyMany companies study it; this page follows only the 54 they lead. All 266 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 30, 200254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only360 open or runningphase 4since Apr 30, 2002Apr 30, 2002none ahead
Viatrisits history only50 open or runningphase 4since Oct 12, 2005Sep 1, 2005none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 2, 2012Jan 2, 2012none ahead
Abbottits history only20 open or runningphase 4since Oct 16, 2003Oct 16, 2003none ahead
AstraZenecaits history only10 open or runningphase 3since May 2, 2002May 2, 2002none ahead
HK inno.Nits history only10 open or runningphase 4since May 11, 2014May 11, 2014none ahead
Joint Stock Company "Farmak"its history only10 open or runningphase 1since Nov 15, 2021Nov 15, 2021none ahead
Neurelisits history only10 open or runningphase 1since Sep 6, 2024Sep 6, 2024none ahead
Orexigen Therapeutics10 open or runningphase 2since Aug 12, 2008Aug 12, 2008none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 3since Mar 27, 2023Mar 27, 2023none ahead

Also a collaborator on its studies: Pfizer and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Orexigen Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2008First study: phase 2 study in SchizophreniaFirst studyNCT00734435 · 26 enrolled · United States

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Studies

The one study Orexigen Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00734435Schizophrenia · United States2TerminatedDec 200826

How it is read

Names in the registry

  • “Olanzapine”, 33 entries
  • “olanzapine”, 17 entries
  • “ALKS 3831”, 7 entries
  • “Olanzapine Tablets 5 mg”, 2 entries
  • “Olanzapine OD Tablets 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.